N-arylpiperazine derivatives acting as alpha 2B-adrenergic receptor antagonists demonstrate in vitro antiplatelet activity, suggesting a potential novel mechanism for antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
In vitro alpha 2B-AR antagonism warrants further preclinical validation; leaves open translation to clinical antiplatelet efficacy.
Despite the substantial clinical success of aspirin and clopidogrel in secondary prevention of ischemic stroke, up to 40% of patients remain resistant to the available antiplatelet treatment. Therefore, there is an urgent clinical need to develop novel antiplatelet agents with a novel mechanism of action. Recent studies revealed that potent alpha 2B-adrenergic receptor (alpha 2B-ARs) antagonists could constitute alternative antiplatelet therapy. We have synthesized a series of N-arylpiperazine derivatives of 4,4-dimethylisoquinoline-1,3(2H,4H)-dione as potential alpha 2B receptor antagonists. The most potent compound 3, effectively inhibited the platelet-aggregation induced both by collagen and ADP/adrenaline with IC50 of 26.9 μM and 20.5 μM respectively. Our study confirmed that the alpha 2B-AR antagonists remain an interesting target for the development of novel antiplatelet agents with an alternative mechanism of action.
No takes yet. Share an insight, caveat, or question.
Marcinkowska et al. (2018) studied Cardiovascular diseases. Compound 3 (alpha 2B-AR antagonist) vs. ARC-239 was evaluated on Inhibition of platelet-aggregation induced by collagen (IC50 in μM).
Synapse has enriched 10 related papers. Consider them for comparative context: